Skip to main content
Medy-Tox Inc. logo

Medy-Tox Inc. — Investor Relations & Filings

Ticker · 086900 ISIN · KR7086900008 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2026-03-03 Major Shareholding Noti…
Country KR South Korea
Listing KO 086900

About Medy-Tox Inc.

https://www.medytox.com/?site_id=en

Medy-Tox Inc. is a biopharmaceutical company focused on the research, development, and commercialization of biologic products. Its primary offerings are centered on botulinum toxin type A (BTX-A) formulations, including Neuronox®, INNOTOX®, Coretox®, and NEWLUX®, which are used for both aesthetic and therapeutic applications. The company is noted for developing the world's first liquid-injectable botulinum toxin. In addition to its toxin portfolio, Medy-Tox manufactures and markets a line of hyaluronic acid (HA) dermal fillers, such as Neuramis®, Atiere, and Potenfill. The company's product range also extends to dermocosmetics under the NEURADERM brand.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document details changes in share ownership (specifically a decrease due to the exercise of early redemption rights on RCPS) by NV7 Holdings, Ltd. in Medytox. This falls under the category of Major Shareholding Notification (MRQ) as it tracks significant ownership thresholds and changes.
2026-03-03 Korean
[기재정정]주식소각결정 (상환전환우선주)
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing from Medytox regarding a 'Decision on Stock Cancellation' (주식소각 결정) for Redeemable Convertible Preference Shares (RCPS). It details the correction of the scheduled cancellation date and confirms the payment of the redemption amount. This type of corporate action, involving the reduction of shares through cancellation, falls under capital structure changes. While it relates to capital, it is specifically a share cancellation announcement, which is best categorized under 'Share Issue/Capital Change' (SHA) as it pertains to the modification of the company's issued share capital.
2026-02-23 Korean
자기주식취득결과보고서
Transaction in Own Shares Classification · 1% confidence The document is a '자기주식취득결과보고서' (Report on the Results of Treasury Stock Acquisition) filed with the Financial Supervisory Service (FSS) in South Korea. It details the specific dates, quantities, and prices of shares repurchased by Medytox. This falls under the category of a company reporting the buyback of its own shares, which corresponds to the 'Transaction in Own Shares' (POS) category.
2026-02-13 Korean
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding a 'Decision to Acquire Treasury Shares' (자기주식 취득 결정). This is a formal regulatory disclosure by Medy-Tox Inc. detailing the intent, quantity, price, and method of a share buyback program. According to the filing definitions, documents reporting the company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2026-01-28 Korean
주식소각결정 (상환전환우선주)
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement regarding a 'Decision to Cancel Shares' (주식소각 결정) by Medytox. It details the cancellation of redeemable convertible preferred shares, including the number of shares, the total amount, the method of acquisition (off-market purchase), and the scheduled date. This falls under capital structure changes and corporate actions related to share cancellation, which is best classified as a share issue/capital change announcement (SHA).
2026-01-23 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Regulatory Filings
2025-11-10 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.